Atypical hemolytic-uremic syndrome (aHUS) / Síndrome hemolítico urémico atípico (SHUa)
Acta méd. colomb
; 44(4): 42-44, Oct.-Dec. 2019. tab
Article
in English
| LILACS, COLNAL
| ID: biblio-1124060
Responsible library:
CO70
ABSTRACT
Abstract Atypical hemolytic-uremic syndrome (aHUS) is a diagnosis of exclusion which should be proposed in cases where there is microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury. It is associated with mutations which cause dysregulation of the complement system and implies an adverse prognosis and a high risk of progression to chronic kidney disease. Following, we present the case of a patient with aHUS, highlighting the effect and importance of biologic therapy with the monoclonal antibody eculizumab. (Acta Med Colomb 2019; 44. DOIhttps//doi.org/10.36104/amc.2019.1301).
RESUMEN
Resumen El síndrome hemolítico urémico atípico (SHUa) constituye un diagnóstico de exclusión que debe plantearse ante la presencia de anemia hemolítica microangiopática, trombocitopenia y lesión renal aguda. Está asociado con mutaciones que provocan una disregulación del sistema del complemento e implica un pronóstico adverso y alto riesgo de progresión a enfermedad renal crónica. A continuación, presentamos el caso de un paciente con SHUa resaltando el efecto e importancia de la terapia biológica con el anticuerpo monoclonal eculizumab. (Acta Med Colomb 2019; 44. DOIhttps//doi.org/10.36104/amc.2019.1301).
Full text:
Available
Collection:
International databases
Database:
COLNAL
/
LILACS
Main subject:
Atypical Hemolytic Uremic Syndrome
Type of study:
Prognostic study
Limits:
Adult
Language:
English
Journal:
Acta méd. colomb
Journal subject:
Medicine
Year:
2019
Document type:
Article
Affiliation country:
Colombia
Institution/Affiliation country:
Universidad Industrial de Santander/CO
/
Universidad del Magdalena/CO